FindMyKOL
Clinical trialNCT06563596RecruitingPhase 2Interventional

Epco, Zanu, Ritux for R/R FL or MZL

SponsorReid Merryman, MDEnrollment45Follicular LymphomaLymphomaMarginal Zone LymphomaNon-Hodgkin LymphomaRefractory LymphomaRelapsed Lymphoma
View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

The purpose of this study is to determine how effective and safe the combination of epcoritamab, zanubrutinib, and rituximab is in treating participants with relapse or refractory Follicular Lymphoma (FL) or marginal zone lymphoma (MZL). * The names of the study drugs involved in this research study are: * Epcoritamab (a type of antibody) * Zanubrutinib (a type of Bruton tyrosine kinase inhibitor) * Rituximab (a type of monoclonal antibody)
clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

3 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States
  • Dana-Farber Cancer Institute

    Boston, Massachusetts, United States

    Reid Merryman, MD
    Recruiting
  • Memorial Sloan Kettering Cancer Center

    New York, New York, United States

    Paola Ghione, MD
    Recruiting
  • the Ohio State University Wexner Medical Center

    Columbus, Ohio, United States

    Yazeed Sawalha, MD
    Recruiting

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Epcoritamab →Rituximab →Zanubrutinib →
Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
21 Jan 2025
Primary completion
1 Mar 2028
Completion
1 Mar 2030
Last update posted
19 Feb 2026
Registered enrollment
45
Registry id
NCT06563596
clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.